Literature DB >> 16870792

In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections.

Ellie J C Goldstein1, Diane M Citron, Yumi A Warren, Kerin L Tyrrell, C Vreni Merriam, Helen T Fernandez.   

Abstract

Tests of dalbavancin's in vitro activity against 209 aerobic and 120 anaerobic isolates from pretreatment diabetic foot infections showed an MIC(90) of < or =0.125 microg/ml against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and 120 anaerobes (Clostridium perfringens, other clostridia, Peptoniphilus asaccharolyticus, Finegoldia magna, and Anaerococcus prevotii), compared to respective MIC(90)s for MSSA and MRSA of 0.5 and 1 microg/ml for vancomycin, 4 and 4 microg/ml for linezolid, 0.5 and 0.5 microg/ml for daptomycin, and 0.25 and >8 microg/ml for clindamycin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16870792      PMCID： PMC1538693          DOI： 10.1128/AAC.00286-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections.

Authors:  Ellie J C Goldstein; Diane M Citron; Yumi A Warren; Kerin L Tyrrell; C Vreni Merriam; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases.

Authors:  E J Goldstein; D M Citron; C A Nesbit
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

3.  High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections.

Authors:  Bradley W Frazee; Jeremy Lynn; Edwin D Charlebois; Larry Lambert; Derrick Lowery; Francoise Perdreau-Remington
Journal:  Ann Emerg Med       Date:  2005-03       Impact factor: 5.721

4.  Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004).

Authors:  Ronald N Jones; Matthew G Stilwell; Helio S Sader; Thomas R Fritsche; Beth P Goldstein
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01-19       Impact factor: 2.803

5.  Antistaphylococcal activity of dalbavancin, an experimental glycopeptide.

Authors:  Gengrong Lin; Kim Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.

Authors:  Luis E Jauregui; Simon Babazadeh; Elyse Seltzer; Lisa Goldberg; Dainis Krievins; Mark Frederick; David Krause; Igors Satilovs; Zilvinas Endzinas; Jeffrey Breaux; William O'Riordan
Journal:  Clin Infect Dis       Date:  2005-10-06       Impact factor: 9.079

7.  Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates.

Authors:  Jennifer M Streit; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-02       Impact factor: 2.803

8.  Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections.

Authors:  Elyse Seltzer; Mary Beth Dorr; Beth P Goldstein; Marc Perry; James A Dowell; Tim Henkel
Journal:  Clin Infect Dis       Date:  2003-10-17       Impact factor: 9.079

9.  Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.

Authors:  B P Goldstein; G Candiani; T M Arain; G Romanò; I Ciciliato; M Berti; M Abbondi; R Scotti; M Mainini; F Ripamonti
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

10.  Methicillin-resistant Staphylococcus aureus in community-acquired skin infections.

Authors:  Gregory J Moran; Ricky N Amii; Frederick M Abrahamian; David A Talan
Journal:  Emerg Infect Dis       Date:  2005-06       Impact factor: 6.883
View more
  25 in total

1.  In vitro activity of TD-1792, a multivalent glycopeptide-cephalosporin antibiotic, against 377 strains of anaerobic bacteria and 34 strains of Corynebacterium species.

Authors:  Kerin L Tyrrell; Diane M Citron; Yumi A Warren; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

Review 2.  Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens.

Authors:  Biswadeep Das; Chayna Sarkar; Debasmita Das; Amit Gupta; Arnav Kalra; Shubham Sahni
Journal:  Ther Adv Infect Dis       Date:  2017-03-08

3.  Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.

Authors:  Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jeng Teng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

4.  New drugs to treat skin and soft tissue infections.

Authors:  Gary E Stein
Journal:  Curr Infect Dis Rep       Date:  2007-09       Impact factor: 3.725

5.  Dalbavancin (zeven), a novel glycopeptide for resistant gram-positive organisms.

Authors:  Jennifer Colabella; Larisa Chagan
Journal:  P T       Date:  2008-01

Review 6.  Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.

Authors:  Andreas Ambrosch; Simone Haefner; Edward Jude; Ralf Lobmann
Journal:  Int Wound J       Date:  2011-08-23       Impact factor: 3.315

7.  Activity of dalbavancin tested against Staphylococcus spp. and beta-hemolytic Streptococcus spp. isolated from 52 geographically diverse medical centers in the United States.

Authors:  Douglas J Biedenbach; James E Ross; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

8.  Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.

Authors:  F D Wang; C H Liao; Y T Lin; W H Sheng; P R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-06-15       Impact factor: 3.267

9.  Management of diabetic foot infections in an era of increasing microbial resistance.

Authors:  Sandra Bliss Nelson
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725

10.  Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

Authors:  Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Li-Ching Yen; Hsiu-Ying Lin; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.